because vrtx is hoping to use data from a phase 3 naive trial as safety data in conjunction with efficacy and safety data from phase II for their NDA...so there will be safety data on WAY more than 1000 patients. Therefore initiating an exploratory polymerase-protease in a more difficult to treat population like tx-refractory, particularly if prove 3 data leaves much to be desired, shouldn't impact on timing of the initial submission just my guess..if it happens (polymerase-protease-soc combos) this is the scenario in which i could definitely see it initiated prior to phase 4
Market Data 
Markets 
AI
